Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Interest & Investment Income (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Interest & Investment Income data on record, last reported at $7.0 million in Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 37.38% year-over-year to $7.0 million; the TTM value through Sep 2025 reached $15.7 million, down 47.84%, while the annual FY2024 figure was $25.5 million, 12.76% up from the prior year.
  • Interest & Investment Income reached $7.0 million in Q3 2025 per ZNTL's latest filing, down from $9.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $34.9 million in Q1 2024 and bottomed at -$22.9 million in Q2 2024.
  • Average Interest & Investment Income over 4 years is $4.5 million, with a median of $4.1 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: surged 949.76% in 2023, then crashed 613.66% in 2024.
  • A 4-year view of Interest & Investment Income shows it stood at $3.2 million in 2022, then surged by 111.88% to $6.8 million in 2023, then tumbled by 68.28% to $2.2 million in 2024, then soared by 224.26% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $7.0 million in Q3 2025, $9.2 million in Q2 2025, and -$2.7 million in Q1 2025.